Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
International Urology and Nephrology
Published in: International Urology and Nephrology 4/2007

01-12-2007 | Original Article

Hepatitis G virus exposure in dialysis patients

Authors: Ali Eslamifar, Rasool Hamkar, Amitis Ramezani, Farrokhlagha Ahmadi, Latif Gachkar, Somayeh Jalilvand, Ladan Adibi, Shahnaz Atabak, Ali Khameneh, Ramin Ghadimi, Arezoo Aghakhani

Published in: International Urology and Nephrology | Issue 4/2007

Login to get access

Abstract

Background

Hepatitis G virus (HGV) is a blood-borne virus. The predominant route of its transmission is parenteral. The aim of this study was to assess the frequency of HGV exposure in haemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD) patients in Iran.

Methods

This study was performed in a major dialysis centre in Tehran, Iran. The study cohort consisted of 77 patients on HD and 13 patients on CAPD. The presence of anti-HGV envelope protein E2 (anti-E2) in the blood serum, as determined by means of an ELISA assay, indicated HGV exposure. All patients were also screened for hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (anti-HBs) and hepatitis C antibody (anti-HCV). In patients who tested positive for anti-E2, HGV RNA was detected by RT-PCR using primers derived from the NS5A region of the viral genome.

Results

In total, 3.89% of the HD patients and none of the CAPD patients tested positive for anti-E2. None of the patients tested positive for HGV RNA. The mean age of the anti-E2-positive patients was 53.3 ± 26.5 years, with 66.66% having previously received blood transfusion. The mean duration of dialysis of the anti-E2-positive patients was 68 ± 64 months. Co-infection with HCV or HBV was not observed in the anti-E2 positive patients.

Conclusion

The rate of exposure to HGV was low among the dialysis patients in our study. The appearance of anti-E2 was accompanied by clearance of serum HGV-RNA. No relationship was noted between HGV exposure and age, sex, history of blood transfusion, time on dialysis and HCV or HBV markers.
Literature
1.
Simons JN, Leary TP, Dawson GJ et al (1995) Isolation of novel virus-like sequences associated with human hepatitis. Nat Med 1:564–569PubMedCrossRef
2.
Linnen J, Wages J, Zhang-Keck ZY et al (1996) Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 271:505–508PubMedCrossRef
3.
Roth WK, Waschk D, Marx S et al (1997) Prevalence of hepatitis G virus and its strain variant, the GB agent, in blood donations and their transmission to recipients. Transfusion 37:651–656PubMedCrossRef
4.
Katayama K, Kageyama T, Fukushi S et al (1998) Full-length GBV-C/HGV genomes from nine Japanese isolate: characterization by comparative analyses. Arch Virol 143:1063–1075PubMedCrossRef
5.
Li G, Ma HH, Lau GK, Leung YK, Yao CL, Chong YT, Tang WH Yao JL (2002) Prevalence of hepatitis G virus infection and homology of different viral strains in Southern China. World J Gastroenterol 8:1081–1087
6.
Lefrère JJ, Roudot TF, Morand JL, Brossard Y et al (1999) Prevalence of GB virus type C/hepatitis G virus RNA and of anti-E2 in individuals at high or low risk for blood-borne or sexually-transmitted viruses: evidence of sexual and parenteral transmission. Transfusion 39:83–94PubMedCrossRef
7.
Lefrere JJ, Sender A, Mercier B et al (2000) High rate of GB virus type C/HGV transmission from mother to infant: possible implications for the prevalence of infection in blood donors. Transfusion 40:602–607PubMedCrossRef
8.
Chen M, Sonnerborg A, Johansson B, Sallberg M (1997) Detection of hepatitis G virus (GB virus C) RNA in human saliva. J Clin Microbiol 35:973–975PubMed
9.
Seemayer CA, Viazov S, Philipp T, Roggendorf M (1998) Detection of GBV-C/HGV RNA in saliva and serum, but not in urine of infected patients. Infection 26:39–41PubMed
10.
Yashina TL, Favorov MO, Khudyakov YE et al (1997) Detection of hepatitis G virus (HGV) RNA: clinical characteristics of acute HGV infection. J Infect Dis 175:1302–1306PubMedCrossRef
11.
Ling BH, Zhuang H, Cui YH et al (1998) A cross-sectional study on HGV infection in a rural population. World J Gastroenterol 4:489–492PubMed
12.
Moaven LD, Locarnini SA, Bowden DS et al (1997) Hepatitis G virus and fulminant hepatic failure: infection. J Hepatol 27:613–619PubMedCrossRef
13.
Sheng L, Soumillion A, Beckers N et al (1998) Hepatitis G virus infection in acute fulminant hepatitis: prevalence of HGV infection and sequence analysis of a specific viral strain. J Viral Hepatitis 5:301–306CrossRef
14.
Corun C, Jadoul M, Loute G, Goubau P (1997) Hepatitis G virus infection in haemodialysis patients: epidemiology and clinical relevance. Nephrol Dial Transplant 12:1326–1329CrossRef
15.
Alter HJ, Nakatsuji Y, Melpolder J et al (1997) The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease. N Engl J Med 336:747–757PubMedCrossRef
16.
Masuko K, Mitsui T, Iwano K et al (1996) Infection with hepatitis GB virus C in patients on maintenance hemodialysis. N Engl J Med 334:1485–1490PubMedCrossRef
17.
De Lamballerie X, Charrel RN (1996) Hepatitis GB virus C in patients on hemodialysis. N Engl J Med 334:1549 PubMedCrossRef
18.
Shibuya A, Takeuchi A, Kamata K et al (1998) Prevalence of hepatitis G virus RNA and anti-E2 in a Japanese haemodialysis population. Nephrol Dial Transplant 13:2033–2036PubMedCrossRef
19.
Schulte-Frohlinde E, Schmolke S, Reindl W et al (1998) Significance of antibodies to recombinant E2 protein of hepatitis G virus in haemodialysis patients. J Viral Hepat 5:341–344PubMedCrossRef
20.
Campo N, Sinelli N, Brizzolara R et al (1999) Hepatitis G virus infection in haemodialysis and in peritoneal dialysis patients. Nephron 82:17–21PubMedCrossRef
21.
Hyunjin N, Kang SW, Choi SH et al (1998) Hepatitis G virus infection in hemodialysis and continuous ambulatory peritoneal dialysis patients. Yonesi Med J 39:116–121
22.
Fabrizi F, De Vecchi AF, Lunghi G et al (2002) Epidemiology of GB virus C/Hepatitis G virus infection in patients on peritoneal dialysis. Perit Dial Int 22:405–410PubMed
23.
Dille BJ, Surowy TK, Gutierrez RA et al (1997) An ELISA for detection of antibodies to the E2 protein of GB virus C. J Infect Dis 175:458–461 PubMed
24.
Tacke M, Kiyosawa K, Stark K et al (1997) Detection of antibodies to a putative hepatitis G virus envelope protein. Lancet 349:318–320PubMedCrossRef
25.
Thomas DL, Vlahov D, Alter HJ et al (1998) Association of antibody to GB virus C (hepatitis G virus) with viral clearance and protection from reinfection. J Infect Dis177:539–542
26.
Sugai Y, Nakayama H, Fukuda M et al (1997) Infection with GB virus C in patients with chronic liver disease. J Med Virol 51:175–181PubMedCrossRef
27.
Andonov A, Sauder C, Jacobsen H, Chaudhary R (1998) Comparison of six sets of PCR primers from two different genomic regions for amplification of GB virus C/hepatitis G virus RNA J Clin Microbiol 36:286–289 PubMed
28.
Goldblum SE, Reed WP (1980) Host defenses and immunologic alternations associated with chronic hemodialysis. Ann Intern Med 93:597–613PubMed
29.
Jacobs C, Brunner FP, Chantler C et al (1977) Combined report on regular dialysis and transplantation in Europe, VII, 1976. Proc Eur Dial Transplant Assoc 14:3–69 PubMed
30.
Sheng L, Widyastuti A, Kosala H et al (1998) High prevalence of hepatitis G virus infection compared with hepatitis C virus infection in patients undergoing chronic hemodialysis. Am J Kidney Dis 31:366–368
31.
Fabrizi F, Martin P (1999) GBV-C/HGV infection in end-stage renal. J Nephrol 12:131–139 PubMed
32.
Cabrerizo M, Bartolome J, de Sequera P et al (1999) GBV-C/HGV-RNA in serum and peripheral blood mononuclear cells in hemodialysis patients. Kidney Int 56:1120–1128PubMedCrossRef
33.
Desassis JF, Laperche S, Girault A et al (1999) Prevalence of present and past hepatitis G virus infection in a French hemodialysis centre. Nephrol Dial Transplant 14:2692–2697PubMedCrossRef
34.
Konomi N, Miyoshi C, Zerain CF et al (1999) Epidemiology of hepatitis B, C, E and G virus infection and molecular analysis of hepatitis G isolates in Bolivia. J Clin Microbiol 37:3291–3295 PubMed
35.
Forns X, Fernandez-Llama P, Costa J et al (1997) Hepatitis G virus infection in a haemodialysis unit: prevalence and clinical implications. Nephrol Dial Transplant 12:956–960 PubMedCrossRef
36.
Bastani B, Frenche D, Gellens M, Di Bisceglie A (1998) Infection with hepatitis G (HGV) and hepatitis C (HCV) viruses in patients on chronic hemodialysis. Am J Nephrol 9:199ACrossRef
37.
Medina M, Ashby M, Schlüter V et al (1998) Prevalence of hepatitis C and G virus infection in chronic hemodialysis patients. Am J Kid Dis 31:224–226PubMed
38.
Desai XX, Pal RB, Banker DD (2004) GB virus C/hepatitis G virus infection in Indian blood donors and high-risk groups. Transfus Apher Sci 30:111–117PubMedCrossRef
39.
Tsuda F, Hadiwandowo S, Sawada N et al (1996) Infection with GB virus C (GBV-C) in patients with chronic liver disease or on maintenance hemodialysis in Indonesia. J Med Virol 49:248–252PubMedCrossRef
40.
Zali MR, Mayumi M, Raoufi M, Nowroozi A (1999) GBV-C infection among patients with hepatitis C virus in the Islamic Republic of Iran: a preliminary report. East Mediterr Health J 5:1023–1029
41.
Huang JJ, Lee WC, Ruaan MK et al (2001) Incidence, transmission, and clinical significance of hepatitis G virus infection in hemodialysis patients. Eur J Clin Microbiol Infect Dis 20:374–379PubMedCrossRef
42.
Pilot-Matias TJ, Carrick RJ, Coleman PF et al (1996) Expression of the GB virus E2 glycoprotein using the Semliki Forest virus vector system and its utility as a serologic marker. Virology 255:282–292CrossRef
43.
Ross RS, Viazov S., Schmitt U et al (1998) Distinct prevalence of antibodies to the E2 protein of GB virus C/hepatitis G virus in different parts of the world (abstr). J Med Virol 54:103–106 PubMedCrossRef
44.
Szabo A, Viazov S, Heemann U et al (1997) GBVC/HGV infection in renal dialysis and transplant patients. Nephrol Dial Transplant 12:2380–2384PubMedCrossRef
45.
Tribl B, Oesterreicher C, Pohanka E et al (1998) GBV-C/HGV in hemodialysis patients: Anti-E2 antibodies and GBV-C/RNA in serum and peripheral blood mononuclear cells. Kidney Int 53:212–216 PubMedCrossRef
46.
Kallinowski B, Ahmadi R, Seipp S et al (1998) Clinical impact of GB-C virus in haemodialysis patients. Nephrol Dial Transplant 13:93–98PubMedCrossRef
47.
Lefrère JJ, Loiseau P, Maury J et al (1997) Natural history of GBV-C/hepatitis G virus infection through the follow-up of GBV-C/hepatitis G virus-infected blood donors and recipients studied by RNA polymerase chain reaction and Anti-E2 serology Blood 90:3776–3780PubMed
48.
Stránský J (1996) Discovery of hepatitis G virus. J Czech Physicians 4:99–101
49.
50.
Hinrichsen H, Leimenstoll G, Stegen G et al (2002) Prevalence of and risk factors for hepatitis G (HGV) infection in haemodialysis patients: a multicentre study. Nephrol Dial Transplant 17:271–275PubMedCrossRef
51.
Wang Y, Chen HS, Fan MH et al (1997) Infection with GB virus C and hepatitis C virus in hemodialysis patients and blood donors in Bejing. J Med Virol 52:26–30PubMedCrossRef
52.
Tanaka E, Alter HJ, Nakatsuji Y et al (1996) Effect of hepatitis G virus infection on chronic hepatitis C. Ann Int Med 125:740–743 PubMed
53.
Martinot M, Marcellin P, Boyer N et al (1997) Influence of hepatitis G virus infection on the severity of liver disease and response to interferon alpha in patients with chronic hepatitis C. Ann Int Med 126:874–881 PubMed
54.
Fabrizi F, Lunghi G, Bacchini G et al (1997) Hepatitis G virus infection in chronic dialysis patients and kidney transplant recipients. Nephrol Dial Transplant 12:1645–1651PubMedCrossRef
55.
Tringali G (1998) Prevalence of HGV infection in hemodialysis patients from eastern Sicily, Giorn. Ital Nefrol 15:141–147
56.
Filho RR, Carneiro M.AS, Teles SA et al (2004) GB virus C/hepatitis G virus infection in dialysis patients and kidney transplant recipients in central Brazil, Mem Inst Oswaldo Cruz 99:639–643
57.
Klusonova H, Pliskova L, Palicka V, Fixa P (2001) Prevalence of viral hepatitis G infection in hemodialysis patients and coinfection with viral hepatitis B and C. Vnitr Lek 47:678–681PubMed
58.
Lopez-Alcorocho JM, Barril G, Ortiz-Movilla N et al (2001) Prevalence of hepatitis B, hepatitis C, GB virus C/hepatitis G and TT viruses in predialysis and hemodialysis patients. J Med Virol 63:103–107PubMedCrossRef
Metadata
Title
Hepatitis G virus exposure in dialysis patients
Authors
Ali Eslamifar
Rasool Hamkar
Amitis Ramezani
Farrokhlagha Ahmadi
Latif Gachkar
Somayeh Jalilvand
Ladan Adibi
Shahnaz Atabak
Ali Khameneh
Ramin Ghadimi
Arezoo Aghakhani
Publication date
01-12-2007
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 4/2007
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-007-9267-x

Other articles of this Issue 4/2007

International Urology and Nephrology 4/2007 Go to the issue

Erratum

A rare complication after circumcision: Keloid of the penis

Original Article

Condom perforation during transrectal ultrasound guided (TRUS) prostate biopsies: a potential infection risk

Original Paper

Pathological review of internal genitalia after anterior exenteration for bladder cancer in women. Evaluating risk factors for female organ involvement

Original Paper

Sonographically documented stable seminoma: a case report

Original Paper

The effectiveness of a scientific symposium to change urologists’ attitude towards treatment of LUTS/BPH

Original Paper

Evaluation and reconstruction of an extremely rare genitourinary abnormality
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits